Lb Pharmaceuticals (LBRX) Current Assets (2024 - 2026)

Lb Pharmaceuticals' Current Assets history runs 3 years deep, the most recent figure standing at $389.1 million for Q1 2026.

• On a quarterly basis, Current Assets changed N/A year-over-year to $389.1 million in Q1 2026; TTM through Mar 2026 was $389.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $308.4 million, up 968.01% from the prior year.
• Current Assets advanced to $389.1 million in Q1 2026 per LBRX's latest filing, from $308.4 million in the prior quarter.
• Across five years, Current Assets topped out at $389.1 million in Q1 2026 and bottomed at $28.9 million in Q4 2024.
• The 3-year median for Current Assets is $312.4 million (2025), against an average of $260.7 million.
• Biggest YoY gain for Current Assets was 968.01% in 2025; the steepest drop was 968.01% in 2025.
• Year by year, Current Assets stood at $28.9 million in 2024, then soared by 968.01% to $308.4 million in 2025, then rose by 26.15% to $389.1 million in 2026.
• Per Business Quant, the three latest LBRX Current Assets figures stand at $389.1 million (Q1 2026), $308.4 million (Q4 2025), and $316.4 million (Q3 2025).